Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-12-18

FDA Approved: NYMALIZE — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for NYMALIZE (nimodipine) by Azurity Pharmaceuticals, Inc. related to the existing nimodipine NDA (NDA 203340).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NYMALIZE (Nimodipine)

Snippet

SUPPL AP for NYMALIZE (NIMODIPINE)